EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s
AbbVie's ROSSINI (NCT06107426) study of its Parkinson's disease combination, Vyalev, has shown promise in a 12-month analysis. The data, which…
AbbVie's ROSSINI (NCT06107426) study of its Parkinson's disease combination, Vyalev, has shown promise in a 12-month analysis. The data, which…